<0> Pharmalucence Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients </0> Pharmalucence, Inc. () has received ...

BEDFORD, Mass.--(BUSINESS WIRE)-- Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include ...

St. Louis, Mo. (June 9, 2014) – Patients with advanced breast cancer that may have spread to their lymph nodes could benefit from a more robust dose of a molecular imaging agent called Tc-99m filtered ...

BILLERICA, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the indication for use of its Sulfur Colloid Injection (SCI) to include localization ...